Ding Linda, Bradford Carla, Kuo I-Lin, Fan Yankhua, Ulin Kenneth, Khalifeh Abdulnasser, Yu Suhong, Liu Fenghong, Saleeby Jonathan, Bushe Harry, Smith Koren, Bianciu Camelia, LaRosa Salvatore, Prior Fred, Saltz Joel, Sharma Ashish, Smyczynski Mark, Bishop-Jodoin Maryann, Laurie Fran, Iandoli Matthew, Moni Janaki, Cicchetti M Giulia, FitzGerald Thomas J
Department of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Department of Biomedical Informatics, University of Arkansas, Little Rock, AR, United States.
Front Oncol. 2022 Aug 10;12:931294. doi: 10.3389/fonc.2022.931294. eCollection 2022.
The future of radiation oncology is exceptionally strong as we are increasingly involved in nearly all oncology disease sites due to extraordinary advances in radiation oncology treatment management platforms and improvements in treatment execution. Due to our technology and consistent accuracy, compressed radiation oncology treatment strategies are becoming more commonplace secondary to our ability to successfully treat tumor targets with increased normal tissue avoidance. In many disease sites including the central nervous system, pulmonary parenchyma, liver, and other areas, our service is redefining the standards of care. Targeting of disease has improved due to advances in tumor imaging and application of integrated imaging datasets into sophisticated planning systems which can optimize volume driven plans created by talented personnel. Treatment times have significantly decreased due to volume driven arc therapy and positioning is secured by real time imaging and optical tracking. Normal tissue exclusion has permitted compressed treatment schedules making treatment more convenient for the patient. These changes require additional study to further optimize care. Because data exchange worldwide have evolved through digital platforms and prisms, images and radiation datasets worldwide can be shared/reviewed on a same day basis using established de-identification and anonymization methods. Data storage post-trial completion can co-exist with digital pathomic and radiomic information in a single database coupled with patient specific outcome information and serve to move our translational science forward with nimble query elements and artificial intelligence to ask better questions of the data we collect and collate. This will be important moving forward to validate our process improvements at an enterprise level and support our science. We have to be thorough and complete in our data acquisition processes, however if we remain disciplined in our data management plan, our field can grow further and become more successful generating new standards of care from validated datasets.
放射肿瘤学的未来前景非常广阔,由于放射肿瘤治疗管理平台取得了非凡进展以及治疗实施方面的改进,我们越来越多地参与到几乎所有肿瘤疾病部位的治疗中。由于我们的技术以及始终如一的准确性,压缩放射肿瘤治疗策略正变得越来越普遍,这得益于我们能够成功治疗肿瘤靶点并更好地避免正常组织受照。在包括中枢神经系统、肺实质、肝脏和其他部位在内的许多疾病部位,我们的服务正在重新定义护理标准。由于肿瘤成像技术的进步以及将综合成像数据集应用于复杂的规划系统,疾病的靶向性得到了改善,这些系统可以优化由专业人员创建的基于体积的治疗计划。由于基于体积的弧形治疗,治疗时间显著缩短,并且通过实时成像和光学跟踪确保了定位的准确性。对正常组织的避让使得治疗计划得以压缩,从而使患者的治疗更加便捷。这些变化需要进一步研究以进一步优化护理。由于全球数据交换是通过数字平台和棱镜进行的,世界各地的图像和放射数据集可以使用既定的去识别和匿名化方法在同一天进行共享/审查。试验完成后的数据存储可以与数字病理和放射组学信息共存于一个单一数据库中,并结合患者特定的结局信息,通过灵活的查询元素和人工智能推动我们的转化科学向前发展,以便更好地对我们收集和整理的数据提出问题。这对于在企业层面验证我们的流程改进并支持我们的科学发展将非常重要。我们必须在数据采集过程中做到全面和完整,然而,如果我们在数据管理计划中保持严谨,我们的领域可以进一步发展并取得更大成功,从经过验证的数据集中生成新的护理标准。